Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships

The Journal of Antimicrobial Chemotherapy
Sahand ImaniIndy Sandaradura

Abstract

To determine the existence of concentration-toxicity relationships for common β-lactam antibiotic adverse effects and define thresholds above which toxicity is more likely. Retrospective review of consecutive patients treated with piperacillin, meropenem or flucloxacillin who underwent therapeutic drug monitoring (TDM) at St Vincent's Hospital (Sydney, Australia) between January 2013 and December 2015. Adverse events investigated included neurotoxicity, nephrotoxicity, hepatotoxicity and opportunistic Clostridium difficile infection. Toxicity was measured using observational grading criteria, clinical assessment and relevant serum biomarkers. These findings were correlated with trough TDM measurements at the time of toxicity presentation. TDM results from 378 patients (piperacillin = 223, meropenem = 94 and flucloxacillin = 61) were investigated. There was no difference in baseline patient characteristics across antibiotic groups. A statistically significant elevation in mean serum trough concentrations (Cmin) was found in patients diagnosed with neurotoxicity (piperacillin, P < 0.01; meropenem, P = 0.04; flucloxacillin, P = 0.01) and those who developed nephrotoxicity whilst being treated with piperacillin (P < 0.01) or merope...Continue Reading

References

Jan 1, 1976·Acta neurochirurgica·G Teasdale, B Jennett
Jun 1, 1993·Journal of Neurosurgery·T O Grøndahl, I A Langmoen
Jan 23, 1998·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·B M Tune
Mar 12, 2003·Pharmacotherapy·Kai Ming ChowPhilip Kam-Tao Li
Apr 23, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthew Ka Hang TongTze-Hoi Kwan
Nov 9, 2004·American Journal of Respiratory and Critical Care Medicine·Corinne AlbertiUNKNOWN European Sepsis Study Group
Nov 2, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K M ChowC C Szeto
May 15, 2007·The American Journal of the Medical Sciences·Chin-Sheng LinShih-Hua Lin
Sep 17, 2008·Toxicology·Elise Andrews, Ann K Daly
Nov 6, 2008·Critical Care : the Official Journal of the Critical Care Forum·Thomas G Slama
Jun 2, 2009·Nature Genetics·Ann K DalyUNKNOWN International SAE Consortium
Jan 29, 2010·Infection·J M LeitnerF Thalhammer
Apr 20, 2011·British Journal of Clinical Pharmacology·Marie F Grill, Rama K Maganti
May 6, 2011·Clinical Pharmacology and Therapeutics·G P AithalA K Daly
Aug 13, 2011·British Journal of Clinical Pharmacology·Jason A RobertsJennifer H Martin
Sep 15, 2011·Critical Care : the Official Journal of the Critical Care Forum·Joao Gonçalves-Pereira, Pedro Póvoa
Oct 25, 2011·Journal of the American Society of Nephrology : JASN·Sushrut S WaikarJoseph V Bonventre
Jan 10, 2012·Expert Opinion on Drug Safety·Philippe Lagacé-Wiens, Ethan Rubinstein
Mar 14, 2012·BMJ Open·Jens-Ulrik Stæhr JensenUNKNOWN Procalcitonin And Survival Study (PASS) Group
May 19, 2012·Trends in Microbiology·Robert A Britton, Vincent B Young
Feb 16, 2013·Expert Review of Anti-infective Therapy·Nicolas AdamTarek Sharshar
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Kevin A BrownDavid N Fisman
Jun 4, 2013·Renal Failure·JiSheng ZhangBeiYan Bao
Sep 17, 2013·Pediatric Blood & Cancer·Jennifer A PrattMichael J Burke
Nov 10, 2013·Critical Care : the Official Journal of the Critical Care Forum·Jennifer E FugateAlejandro A Rabinstein
Feb 19, 2016·Neurology·Shamik BhattacharyyaAaron L Berkowitz

❮ Previous
Next ❯

Citations

Apr 11, 2018·Expert Opinion on Drug Safety·Konstantinos Z VardakasMatthew E Falagas
Apr 17, 2018·The Journal of Antimicrobial Chemotherapy·Sylvain GoutelleOana Dumitrescu
Sep 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Federico Pea
Oct 10, 2018·Current Opinion in Infectious Diseases·Aaron J HeffernanJason A Roberts
Jan 31, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Malini HattiFredrik Resman
Jan 4, 2019·Antimicrobial Agents and Chemotherapy·Julien OllivierDominique Breilh
Sep 29, 2019·Expert Review of Anti-infective Therapy·Renato PascaleFederico Pea
Nov 23, 2019·Expert Review of Anti-infective Therapy·Filippo AnnoniFabio Silvio Taccone
Oct 28, 2019·European Journal of Clinical Pharmacology·Mélanie RappMehdi Oualha
Jun 24, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Tom N Lea-HenryDarren M Roberts
Aug 19, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Sahand ImaniIndy Sandaradura
Jul 1, 2020·Expert Review of Anti-infective Therapy·Sofie DhaeseJan De Waele
Aug 2, 2020·The Journal of Antimicrobial Chemotherapy·A ContejeanD Hirt
Jan 20, 2019·Intensive Care Medicine·Jean-François TimsitFrançois Barbier
Sep 17, 2020·Critical Care : the Official Journal of the Critical Care Forum·Alan AbdullaBirgit C P Koch
Jun 23, 2018·Journal of Neurology·Hilde M H Braakman, Jakko van Ingen
Apr 23, 2020·Expert Review of Clinical Pharmacology·Dario CattaneoDeborah Je Marriott
Jun 17, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jaclyn A CusumanoKerry L LaPlante
Aug 25, 2020·Current Emergency and Hospital Medicine Reports·Boris Garber, Jonathan Glauser
May 16, 2020·The Pediatric Infectious Disease Journal·Amanda GweeStephen B Duffull
Jan 20, 2021·Expert Opinion on Drug Metabolism & Toxicology·Alan AbdullaBirgit C P Koch
Feb 4, 2021·Journal of Clinical Pharmacy and Therapeutics·Nadine A SteffensNatália Brucker
Feb 5, 2021·Clinical Pharmacology and Therapeutics·Kevin J Downes, Jennifer L Goldman
Feb 2, 2021·Clinical Pharmacology and Therapeutics·Silke GastineJoseph F Standing
Mar 25, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Anne-Grete MärtsonJan-Willem C Alffenaar
Mar 13, 2021·Frontiers in Pediatrics·Alan AbdullaMatthijs de Hoog
Mar 19, 2021·Expert Opinion on Drug Metabolism & Toxicology·Marco FioreMaya Hites

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinica Chimica Acta; International Journal of Clinical Chemistry
Yosuke SuzukiJun-ichi Kadota
Journal of the Royal Australian Historical Society
B Dickey
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
F HabibA MacGowan
© 2022 Meta ULC. All rights reserved